 | • レポートコード：MRC2312MG11128 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の標的放射性核種薬剤市場規模と予測を収録しています。・世界の標的放射性核種薬剤市場：売上、2018年-2023年、2024年-2029年 ・世界の標的放射性核種薬剤市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の標的放射性核種薬剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「医薬品」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 標的放射性核種薬剤のグローバル主要企業は、POINT Biopharma、 Telix、 ITM AG、 Bayer AG、 Novartis、 Lantheus、 Curium Pharma、 Fusion Pharmaceuticals、 RadioMedix, Inc.、 Convergent Therapeutics、 IONETIX、 Clarity Pharmaceuticals、 RayzeBio, Inc、 AmbioPharm、 Bracco Imaging、 Navidea、 China Isotope & Radiation Corporation、 Yantai Dongcheng、 Grand Pharma、 Hengrui Medicine、 Yunnan Baiyao Group、 SmartNuclide Biopharma、 Sinotau、 Hexin Pharmaceuticalなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、標的放射性核種薬剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の標的放射性核種薬剤市場：タイプ別、2018年-2023年、2024年-2029年 世界の標的放射性核種薬剤市場：タイプ別市場シェア、2022年 ・医薬品、阻害剤 世界の標的放射性核種薬剤市場：用途別、2018年-2023年、2024年-2029年 世界の標的放射性核種薬剤市場：用途別市場シェア、2022年 ・腫瘍、甲状腺、その他 世界の標的放射性核種薬剤市場：地域・国別、2018年-2023年、2024年-2029年 世界の標的放射性核種薬剤市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における標的放射性核種薬剤のグローバル売上、2018年-2023年 ・主要企業における標的放射性核種薬剤のグローバル売上シェア、2022年 ・主要企業における標的放射性核種薬剤のグローバル販売量、2018年-2023年 ・主要企業における標的放射性核種薬剤のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 POINT Biopharma、 Telix、 ITM AG、 Bayer AG、 Novartis、 Lantheus、 Curium Pharma、 Fusion Pharmaceuticals、 RadioMedix, Inc.、 Convergent Therapeutics、 IONETIX、 Clarity Pharmaceuticals、 RayzeBio, Inc、 AmbioPharm、 Bracco Imaging、 Navidea、 China Isotope & Radiation Corporation、 Yantai Dongcheng、 Grand Pharma、 Hengrui Medicine、 Yunnan Baiyao Group、 SmartNuclide Biopharma、 Sinotau、 Hexin Pharmaceutical ************************************************************* ・調査・分析レポートの概要 標的放射性核種薬剤市場の定義 市場セグメント 世界の標的放射性核種薬剤市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の標的放射性核種薬剤市場規模 世界の標的放射性核種薬剤市場規模：2022年 VS 2029年 世界の標的放射性核種薬剤市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの標的放射性核種薬剤の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の標的放射性核種薬剤製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：医薬品、阻害剤 標的放射性核種薬剤のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：腫瘍、甲状腺、その他 標的放射性核種薬剤の用途別グローバル売上・予測 ・地域別市場分析 地域別標的放射性核種薬剤市場規模 2022年と2029年 地域別標的放射性核種薬剤売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） POINT Biopharma、 Telix、 ITM AG、 Bayer AG、 Novartis、 Lantheus、 Curium Pharma、 Fusion Pharmaceuticals、 RadioMedix, Inc.、 Convergent Therapeutics、 IONETIX、 Clarity Pharmaceuticals、 RayzeBio, Inc、 AmbioPharm、 Bracco Imaging、 Navidea、 China Isotope & Radiation Corporation、 Yantai Dongcheng、 Grand Pharma、 Hengrui Medicine、 Yunnan Baiyao Group、 SmartNuclide Biopharma、 Sinotau、 Hexin Pharmaceutical ... |
This research report provides a comprehensive analysis of the Targeted Radionuclide Drug market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Targeted Radionuclide Drug market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Targeted Radionuclide Drug, challenges faced by the industry, and potential opportunities for market players.
The global Targeted Radionuclide Drug market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Targeted Radionuclide Drug market presents opportunities for various stakeholders, including Tumors, Thyroid. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Targeted Radionuclide Drug market. Additionally, the growing consumer demand present avenues for market expansion.
The global Targeted Radionuclide Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Targeted Radionuclide Drug market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Targeted Radionuclide Drug market.
Market Overview: The report provides a comprehensive overview of the Targeted Radionuclide Drug market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Medicine, Inhibitor), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Targeted Radionuclide Drug market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Targeted Radionuclide Drug market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Targeted Radionuclide Drug market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Targeted Radionuclide Drug market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Targeted Radionuclide Drug market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Targeted Radionuclide Drug market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Targeted Radionuclide Drug, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Targeted Radionuclide Drug market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Targeted Radionuclide Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Medicine
Inhibitor
Market segment by Application
Tumors
Thyroid
Others
Global Targeted Radionuclide Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
POINT Biopharma
Telix
ITM AG
Bayer AG
Novartis
Lantheus
Curium Pharma
Fusion Pharmaceuticals
RadioMedix, Inc.
Convergent Therapeutics
IONETIX
Clarity Pharmaceuticals
RayzeBio, Inc
AmbioPharm
Bracco Imaging
Navidea
China Isotope & Radiation Corporation
Yantai Dongcheng
Grand Pharma
Hengrui Medicine
Yunnan Baiyao Group
SmartNuclide Biopharma
Sinotau
Hexin Pharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Targeted Radionuclide Drug, market overview.
Chapter 2: Global Targeted Radionuclide Drug market size in revenue.
Chapter 3: Detailed analysis of Targeted Radionuclide Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Targeted Radionuclide Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Targeted Radionuclide Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Targeted Radionuclide Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Targeted Radionuclide Drug Overall Market Size
2.1 Global Targeted Radionuclide Drug Market Size: 2022 VS 2029
2.2 Global Targeted Radionuclide Drug Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Targeted Radionuclide Drug Players in Global Market
3.2 Top Global Targeted Radionuclide Drug Companies Ranked by Revenue
3.3 Global Targeted Radionuclide Drug Revenue by Companies
3.4 Top 3 and Top 5 Targeted Radionuclide Drug Companies in Global Market, by Revenue in 2022
3.5 Global Companies Targeted Radionuclide Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Targeted Radionuclide Drug Players in Global Market
3.6.1 List of Global Tier 1 Targeted Radionuclide Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Targeted Radionuclide Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Targeted Radionuclide Drug Market Size Markets, 2022 & 2029
4.1.2 Medicine
4.1.3 Inhibitor
4.2 By Type – Global Targeted Radionuclide Drug Revenue & Forecasts
4.2.1 By Type – Global Targeted Radionuclide Drug Revenue, 2018-2023
4.2.2 By Type – Global Targeted Radionuclide Drug Revenue, 2024-2029
4.2.3 By Type – Global Targeted Radionuclide Drug Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Targeted Radionuclide Drug Market Size, 2022 & 2029
5.1.2 Tumors
5.1.3 Thyroid
5.1.4 Others
5.2 By Application – Global Targeted Radionuclide Drug Revenue & Forecasts
5.2.1 By Application – Global Targeted Radionuclide Drug Revenue, 2018-2023
5.2.2 By Application – Global Targeted Radionuclide Drug Revenue, 2024-2029
5.2.3 By Application – Global Targeted Radionuclide Drug Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Targeted Radionuclide Drug Market Size, 2022 & 2029
6.2 By Region – Global Targeted Radionuclide Drug Revenue & Forecasts
6.2.1 By Region – Global Targeted Radionuclide Drug Revenue, 2018-2023
6.2.2 By Region – Global Targeted Radionuclide Drug Revenue, 2024-2029
6.2.3 By Region – Global Targeted Radionuclide Drug Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Targeted Radionuclide Drug Revenue, 2018-2029
6.3.2 US Targeted Radionuclide Drug Market Size, 2018-2029
6.3.3 Canada Targeted Radionuclide Drug Market Size, 2018-2029
6.3.4 Mexico Targeted Radionuclide Drug Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Targeted Radionuclide Drug Revenue, 2018-2029
6.4.2 Germany Targeted Radionuclide Drug Market Size, 2018-2029
6.4.3 France Targeted Radionuclide Drug Market Size, 2018-2029
6.4.4 U.K. Targeted Radionuclide Drug Market Size, 2018-2029
6.4.5 Italy Targeted Radionuclide Drug Market Size, 2018-2029
6.4.6 Russia Targeted Radionuclide Drug Market Size, 2018-2029
6.4.7 Nordic Countries Targeted Radionuclide Drug Market Size, 2018-2029
6.4.8 Benelux Targeted Radionuclide Drug Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Targeted Radionuclide Drug Revenue, 2018-2029
6.5.2 China Targeted Radionuclide Drug Market Size, 2018-2029
6.5.3 Japan Targeted Radionuclide Drug Market Size, 2018-2029
6.5.4 South Korea Targeted Radionuclide Drug Market Size, 2018-2029
6.5.5 Southeast Asia Targeted Radionuclide Drug Market Size, 2018-2029
6.5.6 India Targeted Radionuclide Drug Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Targeted Radionuclide Drug Revenue, 2018-2029
6.6.2 Brazil Targeted Radionuclide Drug Market Size, 2018-2029
6.6.3 Argentina Targeted Radionuclide Drug Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Targeted Radionuclide Drug Revenue, 2018-2029
6.7.2 Turkey Targeted Radionuclide Drug Market Size, 2018-2029
6.7.3 Israel Targeted Radionuclide Drug Market Size, 2018-2029
6.7.4 Saudi Arabia Targeted Radionuclide Drug Market Size, 2018-2029
6.7.5 UAE Targeted Radionuclide Drug Market Size, 2018-2029
7 Targeted Radionuclide Drug Companies Profiles
7.1 POINT Biopharma
7.1.1 POINT Biopharma Company Summary
7.1.2 POINT Biopharma Business Overview
7.1.3 POINT Biopharma Targeted Radionuclide Drug Major Product Offerings
7.1.4 POINT Biopharma Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.1.5 POINT Biopharma Key News & Latest Developments
7.2 Telix
7.2.1 Telix Company Summary
7.2.2 Telix Business Overview
7.2.3 Telix Targeted Radionuclide Drug Major Product Offerings
7.2.4 Telix Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.2.5 Telix Key News & Latest Developments
7.3 ITM AG
7.3.1 ITM AG Company Summary
7.3.2 ITM AG Business Overview
7.3.3 ITM AG Targeted Radionuclide Drug Major Product Offerings
7.3.4 ITM AG Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.3.5 ITM AG Key News & Latest Developments
7.4 Bayer AG
7.4.1 Bayer AG Company Summary
7.4.2 Bayer AG Business Overview
7.4.3 Bayer AG Targeted Radionuclide Drug Major Product Offerings
7.4.4 Bayer AG Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.4.5 Bayer AG Key News & Latest Developments
7.5 Novartis
7.5.1 Novartis Company Summary
7.5.2 Novartis Business Overview
7.5.3 Novartis Targeted Radionuclide Drug Major Product Offerings
7.5.4 Novartis Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.5.5 Novartis Key News & Latest Developments
7.6 Lantheus
7.6.1 Lantheus Company Summary
7.6.2 Lantheus Business Overview
7.6.3 Lantheus Targeted Radionuclide Drug Major Product Offerings
7.6.4 Lantheus Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.6.5 Lantheus Key News & Latest Developments
7.7 Curium Pharma
7.7.1 Curium Pharma Company Summary
7.7.2 Curium Pharma Business Overview
7.7.3 Curium Pharma Targeted Radionuclide Drug Major Product Offerings
7.7.4 Curium Pharma Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.7.5 Curium Pharma Key News & Latest Developments
7.8 Fusion Pharmaceuticals
7.8.1 Fusion Pharmaceuticals Company Summary
7.8.2 Fusion Pharmaceuticals Business Overview
7.8.3 Fusion Pharmaceuticals Targeted Radionuclide Drug Major Product Offerings
7.8.4 Fusion Pharmaceuticals Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.8.5 Fusion Pharmaceuticals Key News & Latest Developments
7.9 RadioMedix, Inc.
7.9.1 RadioMedix, Inc. Company Summary
7.9.2 RadioMedix, Inc. Business Overview
7.9.3 RadioMedix, Inc. Targeted Radionuclide Drug Major Product Offerings
7.9.4 RadioMedix, Inc. Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.9.5 RadioMedix, Inc. Key News & Latest Developments
7.10 Convergent Therapeutics
7.10.1 Convergent Therapeutics Company Summary
7.10.2 Convergent Therapeutics Business Overview
7.10.3 Convergent Therapeutics Targeted Radionuclide Drug Major Product Offerings
7.10.4 Convergent Therapeutics Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.10.5 Convergent Therapeutics Key News & Latest Developments
7.11 IONETIX
7.11.1 IONETIX Company Summary
7.11.2 IONETIX Business Overview
7.11.3 IONETIX Targeted Radionuclide Drug Major Product Offerings
7.11.4 IONETIX Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.11.5 IONETIX Key News & Latest Developments
7.12 Clarity Pharmaceuticals
7.12.1 Clarity Pharmaceuticals Company Summary
7.12.2 Clarity Pharmaceuticals Business Overview
7.12.3 Clarity Pharmaceuticals Targeted Radionuclide Drug Major Product Offerings
7.12.4 Clarity Pharmaceuticals Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.12.5 Clarity Pharmaceuticals Key News & Latest Developments
7.13 RayzeBio, Inc
7.13.1 RayzeBio, Inc Company Summary
7.13.2 RayzeBio, Inc Business Overview
7.13.3 RayzeBio, Inc Targeted Radionuclide Drug Major Product Offerings
7.13.4 RayzeBio, Inc Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.13.5 RayzeBio, Inc Key News & Latest Developments
7.14 AmbioPharm
7.14.1 AmbioPharm Company Summary
7.14.2 AmbioPharm Business Overview
7.14.3 AmbioPharm Targeted Radionuclide Drug Major Product Offerings
7.14.4 AmbioPharm Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.14.5 AmbioPharm Key News & Latest Developments
7.15 Bracco Imaging
7.15.1 Bracco Imaging Company Summary
7.15.2 Bracco Imaging Business Overview
7.15.3 Bracco Imaging Targeted Radionuclide Drug Major Product Offerings
7.15.4 Bracco Imaging Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.15.5 Bracco Imaging Key News & Latest Developments
7.16 Navidea
7.16.1 Navidea Company Summary
7.16.2 Navidea Business Overview
7.16.3 Navidea Targeted Radionuclide Drug Major Product Offerings
7.16.4 Navidea Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.16.5 Navidea Key News & Latest Developments
7.17 China Isotope & Radiation Corporation
7.17.1 China Isotope & Radiation Corporation Company Summary
7.17.2 China Isotope & Radiation Corporation Business Overview
7.17.3 China Isotope & Radiation Corporation Targeted Radionuclide Drug Major Product Offerings
7.17.4 China Isotope & Radiation Corporation Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.17.5 China Isotope & Radiation Corporation Key News & Latest Developments
7.18 Yantai Dongcheng
7.18.1 Yantai Dongcheng Company Summary
7.18.2 Yantai Dongcheng Business Overview
7.18.3 Yantai Dongcheng Targeted Radionuclide Drug Major Product Offerings
7.18.4 Yantai Dongcheng Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.18.5 Yantai Dongcheng Key News & Latest Developments
7.19 Grand Pharma
7.19.1 Grand Pharma Company Summary
7.19.2 Grand Pharma Business Overview
7.19.3 Grand Pharma Targeted Radionuclide Drug Major Product Offerings
7.19.4 Grand Pharma Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.19.5 Grand Pharma Key News & Latest Developments
7.20 Hengrui Medicine
7.20.1 Hengrui Medicine Company Summary
7.20.2 Hengrui Medicine Business Overview
7.20.3 Hengrui Medicine Targeted Radionuclide Drug Major Product Offerings
7.20.4 Hengrui Medicine Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.20.5 Hengrui Medicine Key News & Latest Developments
7.21 Yunnan Baiyao Group
7.21.1 Yunnan Baiyao Group Company Summary
7.21.2 Yunnan Baiyao Group Business Overview
7.21.3 Yunnan Baiyao Group Targeted Radionuclide Drug Major Product Offerings
7.21.4 Yunnan Baiyao Group Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.21.5 Yunnan Baiyao Group Key News & Latest Developments
7.22 SmartNuclide Biopharma
7.22.1 SmartNuclide Biopharma Company Summary
7.22.2 SmartNuclide Biopharma Business Overview
7.22.3 SmartNuclide Biopharma Targeted Radionuclide Drug Major Product Offerings
7.22.4 SmartNuclide Biopharma Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.22.5 SmartNuclide Biopharma Key News & Latest Developments
7.23 Sinotau
7.23.1 Sinotau Company Summary
7.23.2 Sinotau Business Overview
7.23.3 Sinotau Targeted Radionuclide Drug Major Product Offerings
7.23.4 Sinotau Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.23.5 Sinotau Key News & Latest Developments
7.24 Hexin Pharmaceutical
7.24.1 Hexin Pharmaceutical Company Summary
7.24.2 Hexin Pharmaceutical Business Overview
7.24.3 Hexin Pharmaceutical Targeted Radionuclide Drug Major Product Offerings
7.24.4 Hexin Pharmaceutical Targeted Radionuclide Drug Revenue in Global Market (2018-2023)
7.24.5 Hexin Pharmaceutical Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer